drugset / Trial / NCT07074834
Metoprolol and Trimetazidine for Coronary Heart Disease With Angina
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a prospective, randomized study to evaluate the effectiveness and safety of combining metoprolol succinate with trimetazidine compared to standard therapy for patients with coronary heart disease (CHD) and angina pectoris. The study aims to assess the effects of the combination therapy on inflammatory biomarkers, clinical efficacy, angina symptoms, and left ventricular function over a 3-month treatment-period.
Timeline
- Start
- 2021-02-01
- Primary completion
- 2022-09-30
- Completion
- 2022-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Metoprolol | Other / unclassified | 47.5 mg | Oral |
| Subject | Trimetazidine | Small molecule | — | Oral |
| Background | Aspirin | Small molecule | 0.1 g | Oral |
| Background | Nitroglycerin | Unknown | 0.5 mg | Oral |
| Background | Rosuvastatin | Small molecule | 10 mg | Oral |